Evidence map›Paper›PMID 35815654›Full record

ReviewDrug metabolism reviews2022

Biotransformation novel advances - 2021 year in review.

S Cyrus Khojasteh, Upendra A Argikar, Sungjoon Cho, Rachel Crouch, Carley J S Heck, Kevin M Johnson, Amit S Kalgutkar, Lloyd King, Hlaing Holly Maw, Herana Kamal Seneviratne and 4 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Drug metabolism reviews, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

S Cyrus KhojastehDepartment of Drug Metabolism and Pharmacokinetics, Genentech, Inc, South San Francisco, CA, USA.ORCID 0000-0002-8385-9288
Upendra A ArgikarNon-clinical Development, Bill and Melinda Gates Medical Research Institute, Cambridge, MA, USA.ORCID 0000-0002-0939-0813
Sungjoon ChoDepartment of Drug Metabolism and Pharmacokinetics, Genentech, Inc, South San Francisco, CA, USA.ORCID 0000-0003-1215-9759
Rachel CrouchDepartment of Pharmaceutical Sciences, Lipscomb University College of Pharmacy and Health Sciences, Nashville, TN, USA.ORCID 0000-0002-4525-6072
Carley J S HeckMedicine Design, Pfizer Worldwide Research, Development and Medical, Groton, CT, USA.ORCID 0000-0002-6842-3670
Kevin M JohnsonDepartment of Drug Metabolism and Pharmacokinetics, Genentech, Inc, South San Francisco, CA, USA.ORCID 0000-0003-0479-4242
Amit S KalgutkarMedicine Design, Pfizer Worldwide Research, Development and Medical, Cambridge, MA, USA.ORCID 0000-0001-9701-756X
Lloyd KingQuantitative Drug Discovery, UCB Biopharma UK, Slough, UK.ORCID 0000-0002-3301-7533
Hlaing Holly MawDrug Metabolism and Pharmacokinetics, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA.ORCID 0000-0002-4051-7958
Herana Kamal SeneviratneDepartment of Pharmacology and Molecular Sciences, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0002-7221-7060
Shuai WangDepartment of Drug Metabolism and Pharmacokinetics, Genentech, Inc, South San Francisco, CA, USA.ORCID 0000-0002-3282-1343
Cong WeiDrug Metabolism and Pharmacokinetics, Biogen Inc, Cambridge, MA, USA.ORCID 0000-0003-2310-9255
Donglu ZhangDepartment of Drug Metabolism and Pharmacokinetics, Genentech, Inc, South San Francisco, CA, USA.
Klarissa D JacksonDivision of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, Chapel Hill, NC, USA.ORCID 0000-0002-9388-9800

Funding

Interindividual Variability in Drug Metabolism in Representative PopulationsR35GM143044 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Klarissa D. Jackson · 2021 to 2026
$2.3M
NIGMS NIH HHS R35 GM143044
6 · The paper itself

Abstract

Biotransformation field is constantly evolving with new molecular structures and discoveries of metabolic pathways that impact efficacy and safety. Recent review by Kramlinger et al. (2022) nicely captures the future (and the past) of highly impactful science of biotransformation (see the first article). Based on the selected articles, this review was categorized into three sections: (1) new modalities biotransformation, (2) drug discovery biotransformation, and (3) drug development biotransformation (Table 1).

Indexed as

Drug DiscoveryBiotransformationHumansInactivation, Metabolic

Identifiers

PMID35815654
PMCPMC10249656

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.